Cargando…
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory disease. New treatment strategies that circumvent...
Autores principales: | McCorkle, J. Robert, Gorski, Justin W., Liu, Jinpeng, Riggs, McKayla B., McDowell, Anthony B., Lin, Nan, Wang, Chi, Ueland, Frederick R., Kolesar, Jill M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336885/ https://www.ncbi.nlm.nih.gov/pubmed/34347777 http://dx.doi.org/10.1371/journal.pone.0254205 |
Ejemplares similares
-
Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021) -
Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
por: McDowell, Anthony, et al.
Publicado: (2021) -
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
por: Hill, Kristen S., et al.
Publicado: (2021) -
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020) -
DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden
por: Riggs, McKayla J., et al.
Publicado: (2020)